CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul. 05, 2022 7:56 AM ETCureVac N.V. (CVAC)PFE, BNTXBy: Dulan Lokuwithana, SA News Editor6 Comments

Patents files folder

oonal/iStock via Getty Images

  • German biotech CureVac N.V. (NASDAQ:CVAC) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech (BNTX) and U.S. pharma giant Pfizer (PFE).
  • The case was filed in the German Regional Court in Düsseldorf against BioNTech (BNTX) and two of its subsidiaries, CureVac (CVAC) said, noting it expects fair compensation for the alleged violations.
  • While CureVac (CVAC) has added ~1%, BioNTech (BNTX) and Pfizer (PFE) have each lost ~1% in the pre-market so far.
  • However, the company said it would not seek an injunction or resort to legal action that could disrupt the production and sales of the blockbuster vaccine.
  • The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine, which generated $13.2B in sales in 1Q 2022.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.